Drug class
Extended-half-life recombinant human coagulation factor VIII (Fc–VWF–XTEN fusion protein)
Mechanism of action
Replaces deficient factor VIII in haemophilia A. Activated factor VIII functions as a cofactor for activated factor IX in the tenase complex, accelerating factor X activation and thrombin generation.
General use cases
- Treatment and prophylaxis of bleeding in congenital haemophilia A (factor VIII deficiency), across age groups under the cited EMA product information
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
